In addition, the levels of Alzheimer's disease (AD) biomarkers such as total tau (t-tau), phosphorylated tau (p-tau), and beta-amyloid 1-42 (Aβ1−42) have been previously shown to be decreased or normal in PD patients (17–21). This evidence concerns the gene MAPT and Parkinson disease.